Interferon gamma-1b (recombinant human) 100micrograms/0.5ml solution for injection vials
Requires a prescription from a doctor or prescriber
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Interferon gamma
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Interferon gamma
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Interferon gamma on the MHRA register
Immukin 100micrograms/0.5ml solution for injection vials
WHO defined daily dose (DDD)
40 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(5)
Tuberculosis (NG33)
Tuberculosis (QS141)
Hepatitis B (chronic): diagnosis and management (CG165)
Avapritinib for treating advanced systemic mastocytosis (TA1012)
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 29 · Randomised trials: 4 · 1983–2026
Showing the 50 most relevant studies, sorted by most relevant.
M. Pai, L. Riley, J. Colford
The Lancet. Infectious diseases, 2004
Alice Zwerling, Susan van den Hof, Jerod Scholten, et al.
Thorax, 2011
- Health Personnel
- Tuberculosis
- Antibodies, Bacterial
A. Mandalakas, A. Detjen, A. Hesseling, et al.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2011
Stefano Greco, Enrico Girardi, Raffaele Masciangelo, et al.
PubMed, 2003
- Adenosine Deaminase
- Bayes Theorem
- Clinical Trials as Topic
Talmadge E. King, Carlo Albera, Williamson Z. Bradford, et al.
The Lancet, 2009
- Interferon-gamma
- Analysis of Variance
- Europe
Gudrun Windbichler, H. Hausmaninger, W. Stummvoll, et al.
British Journal of Cancer, 2000
- Antineoplastic Combined Chemotherapy Protocols
- Cisplatin
- Combined Modality Therapy
Flávia Castro, Ana Patrícia Cardoso, Raquel M. Gonçalves, et al.
Frontiers in Immunology, 2018
- Immunologic Surveillance
- Immune Evasion
- Tumor Microenvironment
Gunjan Kak, Mohsin Raza, Brijendra K Tiwari
BioMolecular Concepts, 2018
- Communicable Diseases
- Gene Expression Regulation
- Interferon-gamma
Ling Ni, Jian Lü
Cancer Medicine, 2018
- Immunotherapy
- Immunologic Factors
- Interferon-gamma
Soowon Kang, Hailey Brown, Seungmin Hwang
Immune Network, 2018
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
Interferon gamma signals as an antiparallel homodimeric glycoprotein, acting at…
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 40 of 40 interactions
This cytokine has been found to have effects such as promotion of host response in antitumor immunity, playing roles in all three phases (elimination, equilibrium, and escape) of cancer immunoediting, directly influencing antiproliferation, apoptosis, and antiangiogenesis on tumor cells, and indirectly influencing antitumor immunity. However, currently there is no approved indication report of using interferon gamma in cancer treatment, indicating that interferon has not yet reached a stage of being a clinically-useful antitumor drug.
Interferon gamma, when administered in combination with interferon alpha-2-beta as part of the HerberFERON therapy, is found to have synergistic effects, with the potential for more favorable pharmacodynamics than either alone. This synergy between interferon alpha and gamma include antiproliferative effects on several cancers.
Proteins and enzymes this drug interacts with in the body
PMID:20015550
Associates with transmembrane accessory factor IFNGR2 to form a functional receptor .
PMID:10986460 PMID:2971451 PMID:7615558 PMID:7617032 PMID:7673114
Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signaling components JAK1 and JAK2. In turn, activated JAK1 phosphorylates IFNGR1 to form a docking site for STAT1. Subsequent phosphorylation of STAT1 leads to dimerization, translocation to the nucleus, and stimulation of target gene transcription .
PMID:28883123
STAT3 can also be activated in a similar manner although activation seems weaker.
IFNGR1 intracellular domain phosphorylation also provides a docking site for SOCS1 that regulates the JAK-STAT pathway by competing with STAT1 binding to IFNGR1 (By similarity)
PMID:7615558 PMID:7673114 PMID:8124716
Ligand binding stimulates activation of the JAK/STAT signaling pathway .
PMID:15356148 PMID:7673114 PMID:8124716
Required for signal transduction in contrast to other receptor subunit responsible for ligand binding PMID:7673114
ATC L03AB03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Interferon Gamma
Matched from: Interferon gamma
Additional database identifiers
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5439
GenAtlas
IFNGR1
GeneCards
IFNGR1
GenBank Gene Database
J03143
GenBank Protein Database
306915
UniProt Accession
INGR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5440
GenAtlas
IFNGR2
GeneCards
IFNGR2
GenBank Gene Database
U05875
GenBank Protein Database
463550
UniProt Accession
INGR2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q582356), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.